

# Effectiveness of tailored and conventional therapy in *H. pylori* treatment of Vietnamese patients

<b>Submission date</b> 01/03/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 02/03/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 02/03/2022	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Infection with *Helicobacter pylori* (*H. pylori*) bacteria can lead to a peptic ulcer (a sore on the lining of the stomach, small intestine or food pipe). Tailored therapy has been reported to achieve a higher eradication rate than conventional therapy in treating patients infected with *H. pylori* who have not been treated before. However, there is little information about its effectiveness in patients who previously failed treatment. The aim of this study is to evaluate the *H. pylori* eradication effectiveness of bismuth quadruple therapy and tailored therapy based on antibiotic susceptibility and the CYP2C19 genotype of Vietnamese patients after treatment failure.

### Who can participate?

Patients aged over 18 years old with peptic ulcers who have a record of *H. pylori* treatment failure and a confirmed infection

### What does the study involve?

Participants are randomly allocated into two groups: conventional therapy and tailored therapy. The tailored group are tested for their CYP2C19 genotype and susceptibility for five antibiotics (amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole). The conventional group receive a bismuth quadruple therapy while the tailored group are treated with adjusted medications based on their test results. All participants are treated for 14 days and *H. pylori* eradication is assessed by a breath test after 4 weeks of follow-up.

### What are the possible benefits and risks of participating?

Participants in the tailored group will receive adjusted regimens based on their results of CYP2C19 polymorphism and antibiotic susceptibility that helps to reduce the risk of further treatment failure. All patients may experience side effects from taking medications such as loss of appetite, nausea, fatigue, heartburn, upset stomach, black stools, and a bitter taste.

### Where is the study run from?

University Medical Center, Ho Chi Minh City (Viet Nam)

When is the study starting and how long is it expected to run for?  
September 2014 to June 2017

Who is funding the study?  
Department of Science and Technology of Ho Chi Minh City (Viet Nam)

Who is the main contact?  
Dr Diem My Vu  
diemmyvu@ump.edu.vn

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Diem My Vu

### ORCID ID

<https://orcid.org/0000-0003-4964-2904>

### Contact details

Center for Molecular Biomedicine  
University of Medicine and Pharmacy at Ho Chi Minh City  
217 Hong Bang St, District 5  
Ho Chi Minh  
Viet Nam  
70000  
+84 (0)919789811  
diemmyvu@ump.edu.vn

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

256/QĐ-SKHCHN

## Study information

### Scientific Title

Tailored versus conventional therapy in rescue treatment of Vietnamese patients with *Helicobacter pylori*: a randomized control trial

### Study objectives

Tailored therapy has been reported to achieve a higher eradication rate than conventional therapy in treating naive patients infected with *H. pylori*. However, there is sparse information about its effectiveness in patients who previously failed treatment. Therefore, this study evaluated the *H. pylori* eradication efficacy of bismuth quadruple therapy and tailored therapy based on antibiotic susceptibility and CYP2C19 genotype of Vietnamese patients after treatment failure.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 12/12/2014, The Ethics Committee of University of Medicine and Pharmacy at Ho Chi Minh City (217 Hong Bang St, District 5, Ho Chi Minh City, Vietnam; +84 (0)838535159; nghienquukhoahoc@ump.edu.vn), ref 395/ĐHYD-HĐ

### **Study design**

Randomized controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

*Helicobacter pylori* infection

### **Interventions**

Block randomization with a block size of 10 is used for randomly distributing participants into the two study groups. Patients are randomly assigned to the control group or the tailored group in a 1:1 ratio. The tailored group undergo a gastrointestinal endoscopy, biopsies are collected for the isolation of *H. pylori* and they undergo an analysis of CYP2C19 polymorphism and susceptibility testing for five antibiotics (amoxicillin, clarithromycin, levofloxacin, tetracycline, metronidazole). The conventional group receive a bismuth quadruple regimen while the tailored group is treated with adjusted medications based on their test results. All patients are treated for 2 weeks and supervised for 4 weeks after the treatment is finished. Data are collected every 2 weeks to assess patient compliance and the occurrence of side effects. A urea [<sup>14</sup>C] breath test (PY test) is performed at week 6 for determining *H. pylori* eradication.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Amoxicillin, clarithromycin, levofloxacin, tetracycline, metronidazole, esomeprazol, bismuth

### **Primary outcome(s)**

*H. pylori* eradication determined using a urea [<sup>14</sup>C] breath test (PY test) performed at week 6

### **Key secondary outcome(s)**

1. Antibiotic resistance measured using minimum inhibitory concentration (MIC) test at the first hospital visit after patient enrolment
2. CYP2C19 polymorphism genotyping using real-time PCR and sequencing at the first hospital visit after patient enrolment

### **Completion date**

13/06/2017

## **Eligibility**

### **Key inclusion criteria**

1. Aged 18-95 years old
2. Had a confirmed H. pylori infection by urea breath test or PY test
3. Had a history of H. pylori treatment failure

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

18 years

### **Upper age limit**

95 years

### **Sex**

All

### **Total final enrolment**

540

### **Key exclusion criteria**

1. Younger than 18 years old
2. Received a treatment of antibiotics, antacids, or bismuth-containing drugs within 1 month before the study
3. Had gastric cancer or gastrointestinal bleeding

### **Date of first enrolment**

01/04/2015

### **Date of final enrolment**

31/03/2017

## **Locations**

## Countries of recruitment

Viet Nam

## Study participating centre

University Medical Center, Ho Chi Minh City

215 Hong Bang Street, District 5

Ho Chi Minh

Viet Nam

70000

## Sponsor information

### Organisation

Department of Science and Technology of Ho Chi Minh City

## Funder(s)

### Funder type

Government

### Funder Name

Department of Science and Technology of Ho Chi Minh City

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from Dr Diem My Vu (diemmyvu@ump.edu.vn or diemmyvu@gmail.com) on reasonable request. The data will be available for 5 years after trial completion. Other data (e.g. demographic data, health records, experimental data) collected during the trial will be available upon request and with patient agreement.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes